← All drugs
Drug · FAERS side-effect profile with label screen

Oxycodone And Acetaminophen side effects: what 23,161 FDA adverse event reports show

Oxycodone And Acetaminophen · 1,138 reaction terms · 130,393 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Label matched

Oxycodone (Oxycodone Hydrochloride)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

23,161 reports · 82% serious · 2,940 with death outcome · 55% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.

FDA label, Indications and Usage

What it is

Oxycodone HCl tablets, USP contains oxycodone, an opioid agonist.

FDA label, Description section

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 3Labeled (related wording) 5Reporting / coding artifact 1Lab value / disease marker 6Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,098 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vision abnormal neonatal71182.5
141.5–235.6ROR 183.1 · calibrated p 2e-9 ✓
145.8 EB05 119.5 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious n=71 · 100% consumerno trial arm names this drug
Grip strength38177.5
125.3–251.3ROR 177.8 · calibrated p 3e-9 ✓
138.1 EB05 105.0 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=38 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Dependence8,736169.1
165.9–172.3ROR 270.8 · calibrated p 2e-11 ✓
142.3 EB05 139.8 · IC025 +7.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 100.6 · 100% consumerno trial arm names this drug
Swollen joint count29120.9
82.0–178.1ROR 121.0 · calibrated p 8e-8 ✓
99.8 EB05 72.8 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=29 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Neonatal hypoacusis26112.6
74.9–169.3ROR 112.7 · calibrated p 1e-7 ✓
93.4 EB05 67.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=26 · 100% consumerno trial arm names this drug
Deep vein thrombosis postoperative18493.7
80.5–109.0ROR 94.4 · calibrated p 2e-7 ✓
84.2 EB05 74.4 · IC025 +5.9
3/3 methods agree
Not in label — unassessedserious n=184 · ♀ 100% (drug 55%) · 96% clinicianno trial arm names this drug
Lupus vulgaris10183.9
68.4–102.8ROR 84.3 · calibrated p 5e-7 ✓
75.7 EB05 64.1 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=101 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
X-ray abnormal13272.2
60.5–86.2ROR 72.7 · calibrated p 1e-6 ✓
66.3 EB05 57.3 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious n=132 · ♀ 100% (drug 55%) · 95% clinicianno trial arm names this drug
Duodenal ulcer perforation53971.7
65.7–78.2ROR 73.4 · calibrated p 1e-6 ✓
66.3 EB05 61.7 · IC025 +5.8
3/3 methods agree
Not in label — unassessedserious PRR 46.5 · ♀ 100% (drug 55%) · 93% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody4971.7
53.6–95.8ROR 71.8 · calibrated p 2e-6 ✓
64.8 EB05 51.0 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious n=49 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive51971.3
65.2–77.9ROR 72.9 · calibrated p 1e-6 ✓
65.9 EB05 61.3 · IC025 +5.8
3/3 methods agree
Lab value / disease markerserious PRR 46.5 · ♀ 100% (drug 55%) · 93% clinicianno trial arm names this drug
Adjustment disorder with depressed mood14570.1
59.2–83.0ROR 70.5 · calibrated p 2e-6 ✓
64.5 EB05 56.2 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=145 · ♀ 100% (drug 55%) · 96% clinicianno trial arm names this drug
C-reactive protein6367.5
52.2–87.1ROR 67.7 · calibrated p 3e-6 ✓
61.7 EB05 49.9 · IC025 +5.0
3/3 methods agree
Lab value / disease markerserious n=63 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Learning disability35764.1
57.6–71.3ROR 65.1 · calibrated p 3e-6 ✓
59.7 EB05 54.7 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=357 · 100% consumerno trial arm names this drug
Swollen joint count increased20162.3
54.0–71.8ROR 62.8 · calibrated p 3e-6 ✓
58.0 EB05 51.6 · IC025 +5.4
3/3 methods agree
Lab value / disease markerserious n=201 · ♀ 100% (drug 55%) · 95% clinicianno trial arm names this drug
Dislocation of vertebra13859.8
50.4–71.0ROR 60.2 · calibrated p 5e-6 ✓
55.7 EB05 48.3 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=138 · ♀ 100% (drug 55%) · 94% clinicianno trial arm names this drug
Folliculitis63459.2
54.6–64.0ROR 60.8 · calibrated p 4e-6 ✓
55.5 EB05 51.9 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious PRR 45.8 · ♀ 100% (drug 55%) · 93% clinicianno trial arm names this drug
Porphyria acute7753.4
42.5–67.2ROR 53.6 · calibrated p 1e-5 ✓
49.9 EB05 41.2 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=77 · ♀ 100% (drug 55%) · 92% clinicianno trial arm names this drug
Helicobacter infection55452.0
47.8–56.6ROR 53.2 · calibrated p 9e-6 ✓
49.1 EB05 45.8 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious PRR 36.4 · ♀ 100% (drug 55%) · 94% clinicianno trial arm names this drug
Facet joint syndrome16650.3
43.0–58.7ROR 50.6 · calibrated p 1e-5 ✓
47.4 EB05 41.6 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=166 · ♀ 100% (drug 55%) · 91% clinicianno trial arm names this drug
Ill-defined disorder3,10048.6
47.0–50.3ROR 56.0 · calibrated p 7e-6 ✓
46.1 EB05 44.8 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious PRR 48.7 · 85% consumerno trial arm names this drug
Rheumatic fever21847.5
41.5–54.4ROR 47.9 · calibrated p 2e-5 ✓
45.0 EB05 40.2 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=218 · ♀ 100% (drug 55%) · 94% clinicianno trial arm names this drug
Retinitis7743.7
34.8–54.9ROR 43.9 · calibrated p 4e-5 ✓
41.3 EB05 34.2 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=77 · ♀ 100% (drug 55%) · 100% clinicianno trial arm names this drug
Pemphigus56042.7
39.2–46.4ROR 43.7 · calibrated p 3e-5 ✓
40.7 EB05 38.0 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious PRR 28.7 · ♀ 100% (drug 55%) · 94% clinicianno trial arm names this drug
Developmental delay39140.6
36.7–44.9ROR 41.3 · calibrated p 4e-5 ✓
38.8 EB05 35.7 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 27.7 · 100% consumerno trial arm names this drug
Hand deformity56140.5
37.3–44.1ROR 41.5 · calibrated p 4e-5 ✓
38.8 EB05 36.1 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious PRR 29.6 · ♀ 100% (drug 55%) · 93% clinicianno trial arm names this drug
Drug withdrawal syndrome neonatal61638.8
35.9–42.1ROR 39.9 · calibrated p 5e-5 ✓
37.2 EB05 34.8 · IC025 +5.0
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 26.2 · 100% consumerno trial arm names this drug
Rheumatoid factor positive22236.2
31.7–41.4ROR 36.5 · calibrated p 9e-5 ✓
34.7 EB05 31.1 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious n=222 · ♀ 100% (drug 55%) · 95% clinicianno trial arm names this drug
Product used for unknown indication4735.4
26.5–47.4ROR 35.5 · calibrated p 1e-4 ✓
33.7 EB05 26.3 · IC025 +4.2
3/3 methods agree
Reporting / coding artifactserious n=47 · ♀ 0% (drug 55%)no trial arm names this drug
Presbyacusis1133.2
18.2–60.5ROR 33.2 · calibrated p 5e-4 ✓
30.4 EB05 18.1 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=11no trial arm names this drug
Pericarditis55531.2
28.7–33.9ROR 31.9 · calibrated p 2e-4 ✓
30.1 EB05 28.1 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious PRR 21.3 · ♀ 100% (drug 55%) · 93% clinicianno trial arm names this drug
Substance use disorder9428.5
23.2–35.0ROR 28.6 · calibrated p 4e-4 ✓
27.5 EB05 23.2 · IC025 +4.3
3/3 methods agree
Labeled adverse reaction
exact term
serious n=93 · 100% consumerno trial arm names this drug
Irritable bowel syndrome65028.4
26.3–30.6ROR 29.2 · calibrated p 3e-4 ✓
27.5 EB05 25.8 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious PRR 24.4 · ♀ 98% (drug 55%) · 91% clinicianno trial arm names this drug
Synovitis53627.7
25.4–30.1ROR 28.3 · calibrated p 4e-4 ✓
26.9 EB05 25.0 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious PRR 19.7 · ♀ 100% (drug 55%) · 94% clinicianno trial arm names this drug
Withdrawal syndrome1,14825.3
23.9–26.8ROR 26.5 · calibrated p 5e-4 ✓
24.6 EB05 23.4 · IC025 +4.5
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 24.3 · 98% consumerno trial arm names this drug

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Oxycodone And Acetaminophen only as a background or rescue medication (NCT02625181, NCT04296396); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Dependence8,736169.1
165.9–172.3ROR 270.8 · calibrated p 2e-11 ✓
142.3 EB05 139.8 · IC025 +7.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 100.6 · 100% consumerno trial arm names this drug
Overdose4,11417.5
17.0–18.0ROR 21.1 · calibrated p 0.002 ✓
17.2 EB05 16.8 · IC025 +4.0
3/3 methods agree
Reporting / coding artifactserious PRR 15.2 · 97% consumerno trial arm names this drug
Ill-defined disorder3,10048.6
47.0–50.3ROR 56.0 · calibrated p 7e-6 ✓
46.1 EB05 44.8 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious PRR 48.7 · 85% consumerno trial arm names this drug
Drug ineffective (drug did not work)1,9141.3
1.3–1.4ROR 1.3 · calibrated p 0.538
1.3 EB05 1.3 · IC025 +0.3Reporting / coding artifactserious PRR 1.7no trial arm names this drug
Pain1,8002.7
2.5–2.8ROR 2.8 · calibrated p 0.698
2.6 EB05 2.5 · IC025 +1.3
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious PRR 2.5 · ♀ 76% (drug 55%)no trial arm names this drug
Death1,6681.8
1.7–1.8ROR 1.8 · calibrated p 0.837
1.8 EB05 1.7 · IC025 +0.7Outcome field, not a reaction
boxed warning mentions mortality
serious PRR 1.2 · 83% consumerno trial arm names this drug
Fatigue (tiredness)1,6221.9
1.8–2.0ROR 2.0 · calibrated p 0.921
1.9 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
serious PRR 2.0 · ♀ 80% (drug 55%)no trial arm names this drug
Nausea1,4391.7
1.6–1.7ROR 1.7 · calibrated p 0.766
1.7 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
serious PRR 1.6no trial arm names this drug
Dyspnoea (shortness of breath)1,1711.9
1.8–2.0ROR 1.9 · calibrated p 0.901
1.9 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
serious PRR 1.6 · ♀ 82% (drug 55%)no trial arm names this drug
Withdrawal syndrome1,14825.3
23.9–26.8ROR 26.5 · calibrated p 5e-4 ✓
24.6 EB05 23.4 · IC025 +4.5
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 24.3 · 98% consumerno trial arm names this drug
Drug dependence1,1326.3
6.0–6.7ROR 6.6 · calibrated p 0.116
6.3 EB05 6.0 · IC025 +2.6
3/3 methods agree
Reporting / coding artifactserious PRR 4.5 · 95% consumerno trial arm names this drug
Arthralgia (joint pain)1,0972.4
2.3–2.5ROR 2.5 · calibrated p 0.826
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 2.7 · ♀ 86% (drug 55%)no trial arm names this drug
Off label use (used outside approved label)1,0631.1
1.0–1.2ROR 1.1 · calibrated p 0.382
1.1 EB05 1.1 · IC025 +0.0Reporting / coding artifactserious PRR 1.3no trial arm names this drug
Headache1,0481.5
1.4–1.6ROR 1.5 · calibrated p 0.668
1.5 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
serious PRR 1.6 · ♀ 83% (drug 55%)no trial arm names this drug
Anxiety1,0483.3
3.1–3.5ROR 3.4 · calibrated p 0.499
3.3 EB05 3.2 · IC025 +1.6
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 3.1no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Oxycodone And Acetaminophen?

In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone And Acetaminophen are dependence, ill-defined disorder, pain, fatigue, nausea, dyspnoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Oxycodone And Acetaminophen have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

Do FAERS signals prove that Oxycodone And Acetaminophen causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.